ACT-539313

ACT-539313 · Idorsia Pharmaceuticals Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ACT-539313, covering 2023-03-31 to 2023-03-31. Get the full timeline:

Most recent: Clinical Trial Update: Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder [Phase 2]

See pricing